Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Guelph
$70,000.00
Therapeutic potential of thrombospondin-1 mimetic peptides in epithelial ovarian cancer.
EF 2008-09
Résumé
Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. The disease has been referred to as the "silent killer" because symptoms associated with EOC are often common to minor ailments. EOC has a high mortality rate because it is often not diagnosed until late stages and individuals often become resistant to chemotherapy treatments. It is essential to gain a better understanding of EOC and to identify potential therapeutics which can reduce the high morbidity and mortality associated with this disease. It has been reported that tumours are unable to grow beyond 1-2mm3 without recruiting their own blood supply through a process known as angiogenesis. Over the past decades, anti-angiogenic compounds such as thrombospondin-1 (TSP-1) have been identified as potential anti-cancer agents that may have fewer negative side-effects compared to traditional chemotherapeutics. Due to the large size of TSP-1, smaller peptides were created for their use in clinical trials. It was hypothesized that use of anti-angiogenic compounds would diminish the blood supply to the tumour, inhibiting growth and resulting in regression. Preliminary studies with TSP-1 peptides in our laboratory have revealed that the blood supply to the tumours is not eliminated but instead remodeled or normalized. Due to the rapid growth which tumours exhibit, the vasculature that develops is often irregular which inhibits tissue perfusion and drug delivery. We have also shown that TSP-1 has a direct apoptotic effect on tumour cells and results in significant tumour regression. We propose that TSP-1 peptides normalize the tumour vasculature and increase uptake of conventional drugs such as chemotherapeutics. Our laboratory has developed a mouse model of EOC which we can utilize to test the efficacy of TSP-1 peptides alone or in combination with other agents. Results from these studies will have a significant impact on the way in which individuals are treated with EOC.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184687
Name
Solinger Nicole E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Therapeutic potential of thrombospondin-1 mimetic peptides in epithelial ovarian cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Apoptosis; Cell Proliferation; Cellular Biology; Chemotherapeutics; Epithelial Ovarian Cancer; Molecular Biology; Mouse Model; Tissue Perfusion; Vascular Normalization
Abstract
Epithelial Ovarian Cancer (EOC) is the most lethal gynecological malignancy. The disease has been referred to as the "silent killer" because symptoms associated with EOC are often common to minor ailments. EOC has a high mortality rate because it is often not diagnosed until late stages and individuals often become resistant to chemotherapy treatments. It is essential to gain a better understanding of EOC and to identify potential therapeutics which can reduce the high morbidity and mortality associated with this disease. It has been reported that tumours are unable to grow beyond 1-2mm3 without recruiting their own blood supply through a process known as angiogenesis. Over the past decades, anti-angiogenic compounds such as thrombospondin-1 (TSP-1) have been identified as potential anti-cancer agents that may have fewer negative side-effects compared to traditional chemotherapeutics. Due to the large size of TSP-1, smaller peptides were created for their use in clinical trials. It was hypothesized that use of anti-angiogenic compounds would diminish the blood supply to the tumour, inhibiting growth and resulting in regression. Preliminary studies with TSP-1 peptides in our laboratory have revealed that the blood supply to the tumours is not eliminated but instead remodeled or normalized. Due to the rapid growth which tumours exhibit, the vasculature that develops is often irregular which inhibits tissue perfusion and drug delivery. We have also shown that TSP-1 has a direct apoptotic effect on tumour cells and results in significant tumour regression. We propose that TSP-1 peptides normalize the tumour vasculature and increase uptake of conventional drugs such as chemotherapeutics. Our laboratory has developed a mouse model of EOC which we can utilize to test the efficacy of TSP-1 peptides alone or in combination with other agents. Results from these studies will have a significant impact on the way in which individuals are treated with EOC.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Solinger, Nicole E
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~